Hongxin Piao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hongxin Piao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Anlin Ma
Division of Infectious Diseases, China-Japan Friendship Hospital, Beijing, China
1 shared publication - Bingqiong Wang
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, China
1 shared publication - Guofeng Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Hong You
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
1 shared publication - Hui Ma
Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China
1 shared publication - Huiguo Ding
Department of Gastroenterology and Hepatology, Beijing You’an Hospital Affiliated with Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (6) , 1529-1539
Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis
Background and Aims: Evidence comparing longitudinal liver stiffness measurements (LSMs) dynamics to on-treatment LSM for predicting clinical outcomes in patients receiving etiology therapy is limited. This study aimed to assess the prognostic value of on-treatment LSM in patients with chronic hepatitis B (CHB) receiving antiviral therapy. Approach and Results: This prospective cohort included patients with CHB and significant fibrosis or cirrhosis. Liver-related events (LREs) were defined as hepatic decompensation, liver transplantation, or liver-related death. The association between LREs and baseline, on-treatment, and dynamic changes in LSM was analyzed. A total of 1116 patients with CHB, including 875 (78.4%) diagnosed with cirrhosis, were followed for a median of 7.5 (2.5–9.5) years. On-treatment LSM was the most reliable predictor of 3-year and 5-year outcomes (AUROC: 0.72–0.78) after 1–3 years of antiviral therapy, outperforming baseline LSM (AUROC: 0.59–0.65) and LSM changes (AUROC: 0.42–0.65). Patients with LSM <10 kPa at 1, 2, or 3 years of antiviral therapy have a much lower risk of LREs, with a 5-year cumulative incidence of 2.2%, 2.6%, and 2.7%, respectively. This finding held true in the cirrhosis subgroup, in the validation cohort, and for predicting decompensations alone. Notably, patients with on-treatment LSM <10 kPa showed better restoration of lobular architecture assessed by liver biopsies. Conclusions: On-treatment LSM measured 1–3 years after antiviral therapy offers superior predictive accuracy for LREs compared with baseline or LSM changes, with LSM <10 kPa indicating a significantly lower risk, likely due to improved lobular architecture.
- 1 September 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (6) , 1529-1539
Open AccessEarly on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis
Background and Aims: Evidence comparing longitudinal liver stiffness measurements (LSMs) dynamics to on-treatment LSM for predicting clinical outcomes in patients receiving etiology therapy is limited. This study aimed to assess the prognostic value of on-treatment LSM in patients with chronic hepatitis B (CHB) receiving antiviral therapy. Approach and Results: This prospective cohort included patients with CHB and significant fibrosis or cirrhosis. Liver-related events (LREs) were defined as hepatic decompensation, liver transplantation, or liver-related death. The association between LREs and baseline, on-treatment, and dynamic changes in LSM was analyzed. A total of 1116 patients with CHB, including 875 (78.4%) diagnosed with cirrhosis, were followed for a median of 7.5 (2.5–9.5) years. On-treatment LSM was the most reliable predictor of 3-year and 5-year outcomes (AUROC: 0.72–0.78) after 1–3 years of antiviral therapy, outperforming baseline LSM (AUROC: 0.59–0.65) and LSM changes (AUROC: 0.42–0.65). Patients with LSM <10 kPa at 1, 2, or 3 years of antiviral therapy have a much lower risk of LREs, with a 5-year cumulative incidence of 2.2%, 2.6%, and 2.7%, respectively. This finding held true in the cirrhosis subgroup, in the validation cohort, and for predicting decompensations alone. Notably, patients with on-treatment LSM <10 kPa showed better restoration of lobular architecture assessed by liver biopsies. Conclusions: On-treatment LSM measured 1–3 years after antiviral therapy offers superior predictive accuracy for LREs compared with baseline or LSM changes, with LSM <10 kPa indicating a significantly lower risk, likely due to improved lobular architecture.